-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol, is a novel subtype-selective N-methyl-D-aspartate (NMDA) antagonist that has been characterized in vitro and in vivo. Ro 63-1908 inhibited [ 3 H]dizocilpine ( 3 H-MK-801) binding in a biphasic manner with IC 50 values of 0.002 and 97 M for the high-and low-affinity sites, respectively. Ro 63-1908 selectively blocked recombinant receptors expressed in Xenopus oocytes containing NR1C ϩ NR2B subunits with an IC 50 of 0.003 M and those containing NR1C ϩ NR2A subunits with an IC 50 of Ͼ100 M, thus demonstrating greater than 20,000-fold selectivity for the recombinant receptors expressing NR1C ϩ NR2B. Ro 63-1908 blocked these NMDA NR2B-subtype receptors in an activity-dependent manner. Ro 63-1908 was neuroprotective against glutamate-induced toxicity and against oxygen/glucose deprivation-induced toxicity in vitro with IC 50 values of 0.68 and 0.06 M, respectively. Thus, the in vitro pharmacological characterization demonstrated that Ro 63-1908 was a potent and highly selective antagonist of the NR2B subtype of NMDA receptors. Ro 63-1908 was active against sound-induced seizures (ED 50 ϭ 4.5 mg/kg i.p. when administered 30 min beforehand) in DBA/2 mice. The dose required to give a full anticonvulsant effect did not produce a deficit in the Rotarod test. NMDA-induced seizures were also inhibited by Ro 63-1908 with an ED 50 of 2.31 mg/kg i.v. when administered 15 min before testing. Ro 63-1908 gave a dose-related neuroprotective effect against cortical damage in a model of permanent focal ischemia. Maximum protection of 39% was seen at a plasma concentration of 450 ng/ml. There were, however, no adverse cardiovascular or CNS side-effects seen at this dosing level.
values of 0.68 and 0.06 M, respectively. Thus, the in vitro pharmacological characterization demonstrated that Ro 63-1908 was a potent and highly selective antagonist of the NR2B subtype of NMDA receptors. Ro 63-1908 was active against sound-induced seizures (ED 50 ϭ 4.5 mg/kg i.p. when administered 30 min beforehand) in DBA/2 mice. The dose required to give a full anticonvulsant effect did not produce a deficit in the Rotarod test. NMDA-induced seizures were also inhibited by Ro 63-1908 with an ED 50 of 2.31 mg/kg i.v. when administered 15 min before testing. Ro 63-1908 gave a dose-related neuroprotective effect against cortical damage in a model of permanent focal ischemia. Maximum protection of 39% was seen at a plasma concentration of 450 ng/ml. There were, however, no adverse cardiovascular or CNS side-effects seen at this dosing level.
Native NMDA receptors are composed of an NR1 subunit (can occur as eight different splice variants), which combines with NR2A-D subunits to form heteromeric receptors (for reviews see McBain and Mayer, 1994; Kemp and Kew, 1998) . NMDA receptors are thought to be tetramers that are composed of two NR1 and two NR2 subunits (Laube et al., 1998) , which is compatible with earlier electrophysiological evidence demonstrating that NMDA receptor activation requires occupation of two independent glycine binding sites and two independent glutamate sites (Benveniste and Mayer, 1991; Clements and Westbrook, 1991) . The glutamate and glycine binding sites are believed to be located on the NR2 and NR1 subunits, respectively (Wafford et al., 1995; Hirai et al., 1996; Laube et al., 1997; Anson et al., 1998) . However, the proposed tetrameric stoichiometry of NMDA receptor remains controversial because evidence also exists for a pentameric structure (for review see Kemp and Kew, 1998) .
In the adult rodent and human brain the NR1 subunit is widely distributed throughout the brain, whereas the NR2 subunits are expressed in a distinct spatio-temporal manner (Watanabe et al., 1993; Monyer et al., 1994; Rigby et al., 1996; Wenzel et al., 1997) . The predominant NR2 subunits in the forebrain are NR2A and NR2B, with NR2C expressed largely in the cerebellum and various select nuclei, and NR2D expression is confined to the diencephalon and midbrain (for reviews see McBain and Mayer, 1994; Gill et al., 1999) . Coexpression of NR1 with one or more of the NR2 subunits yields receptors with distinct functional and phar-macological properties that appear to resemble those of native receptors (Priestley et al., 1995; Meddows et al., 2001) . Many compounds have been described that can interact with the NMDA receptor at distinct sites, such as the ionchannel site, the glutamate transmitter recognition site, and the glycine-modulatory site (see Kemp and Kew; . Ligands acting at the glutamate or at the glycine binding site show low selectivity between the different subtypes of receptors (Priestley et al., 1995 , Grimwood et al., 1996 .
Over the last decade much attention has been given to the role of NMDA receptors in neurodegeneration following acute ischemic and traumatic brain injury (for review see Gill et al., 1999) . The marked neurotoxic potential of the NMDA receptor appears to result from its high permeability to calcium, a known mediator of cell damage, its high affinity for glutamate, and its relative lack of desensitization during prolonged activation. The nonselective NMDA antagonists have been studied extensively in the last 10 years both in animal models and in the clinical setting (Muir and Lees, 1995; Lees, 1996 ; for reviews see Gill et al., 1999) . In animal models these compounds have been investigated for possible application in neurodegenerative conditions such as stroke, traumatic brain injury, Parkinson's disease, and epilepsy, and for the treatment of acute pain. Nonselective NMDA antagonists showed robust neuroprotective effects in animal models of stroke. However, the use of nonselective NMDA receptor antagonists showed that blockade of NMDA receptors, besides its potential beneficial effects, produced profound CNS side-effects that have limited their therapeutic utility to date (Muir and Lees, 1995) . In humans, these side-effects range from light-headedness, dizziness, paresthesia, and agitation at low doses, through nystagmus, hallucinations, somnolence, and blood pressure increases at moderate doses, to catatonia and "dissociative anesthesia" at high doses (Muir and Lees, 1995) . These side-effects have limited the doses that could be administered in clinical trials, and as a consequence, plasma drug concentrations that are fully neuroprotective in animal models have been difficult to achieve in humans.
To try to eliminate these side-effects we have targeted the NR2B subunit of the NMDA receptor to develop selective compounds. Antagonists that are selective for the NMDA receptors containing NR2B subunits, such as ifenprodil, CP 101,606, and Ro 25-6981, are able to inhibit 50 to 60% of the 3 H-MK-801 binding to all of the NMDA receptors in adult rat forebrain (Fischer et al., 1997; Mutel et al., 1998) . Furthermore, we have found that these antagonists bind with a higher affinity to activated and desensitized states of the receptor relative to the unliganded resting state and, thus, display an activity-or state-dependent mode of action (Kew et al., 1996; Fischer et al., 1997 Fischer et al., , 1998 . It is predicted that such compounds will preferentially block NMDA receptors, which are continuously activated by sustained high glutamate levels in ischemic brain areas, while leaving those physiologically activated in normal brain areas relatively unaffected.
Here we report the in vitro and in vivo profile of a novel, highly selective and potent blocker of NMDA receptors containing the NR2B subunit, 1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol (Ro 63-1908; Alanine et al., 1999; Fig. 1) . This compound has also been described by Zhou et al. (1999) .
Materials and Methods

Materials
Drugs used in binding, electrophysiological, and toxicity experiments were purchased from the following sources: D-2-amino-5-phosphonopentanoic acid (Tocris Cookson, Inc., Ballwin, MO), flunarizine (Sigma/RBI, Natick, MA), ifenprodil (Sigma/RBI), MK-801(dizocilpine; Sigma/RBI), 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (Tocris Cookson), [1-(2-thienyl) 
Binding Experiments
Binding experiments with rat forebrain membranes and the radioligand 3 H-MK-801 (dizocilpine) were performed as described previously by Ransom and Stec (1988) and Fischer et al. (1997) . Briefly, membranes were prepared from whole brain of male rats (150 -200 g) by homogenization and centrifugation (48,000g for 10 min). For binding experiments, the membranes were washed three times, and the final pellet was re-homogenized in 25 volumes of buffer (original wet weight) and used as such in the assay. The final protein concentration in the assay was 200 g/ml. The incubation was performed in the presence of 1 nM added glutamate, glycine, and spermidine. The ligand, 3 H-MK-801, (ϩ)-[3-3H(N)] (PerkinElmer Life Sciences, Boston, MA), 20 Ci/mmol, was used at 5 nM final concentration. Nonspecific binding was determined in the presence of 100 M TCP. After 2 h of incubation at room temperature, the suspension was filtered (Whatman GF/B, soaked in 0.1% polyethylenimine for 2 h) and washed five times with 3 ml of cold 5 mM Tris-HCl (pH 7.4). The filters were counted with 10 ml of Ultima-gold (Packard BioScience, Meriden, CT) in a Tri-Carb 2500 TR scintillation counter after agitation. The dpm values were transformed to percentage of specific binding. Each experiment was repeated at least three times.
Binding with 3 H-Ro 25-6981 to rat tissue was performed as previously described by Mutel et al. (1998) . Briefly, rat brain membranes, prepared as above, were washed three times in a Tris-HCl (5 mM, pH 7.4) cold binding buffer. The final pellet was resuspended in the same buffer and used at a final concentration of 200 g of protein/ml.
3 H-Ro 25-6981 (5 nM), specific activity, 20.7 Ci/mmol, was used, and the nonspecific binding was determined using 10 M 1-(4-chlorophenyl)-2-methyl-6-methoxy-7-hydroxy-1,2,3,4-tetrahydroisoquinolin (Ro 04-5595). The incubation time was 2 h at 4°C. The assay was stopped by filtration on Whatman GF/B glass fiber filters (Unifilter 96, Canberra Packard S.A., Zurich, Switzerland), and the radioactivity on the filter was measured as above. Each experiment was repeated at least three times.
The analysis of the binding assays was done by fitting the function below to concentration-response relations from individual experiments:
with y, labeled receptor; P low , proportion of low-affinity binding sites; K dlow , affinity of low-affinity binding sites; and K dhigh , affinity of high-affinity binding sites.
Electrophysiology
cDNA clones coding for the subunits NR1C (also termed NMDAR1-2a or NR1 001 ), NR2A, and NR2D of the NMDA receptor were isolated from a rat gt11 cDNA library (see Fischer et al., 1997) . The clone for the subunit NR2B of the rat NMDA receptor was kindly provided by Dr. S. Nakanishi (Kyoto, Japan). The cDNA for NR1F (NMDAR1-2b or NR1 101 ) was derived from NR1C by molecular engineering (Fischer et al., 1997) . The methods for subcloning, nuclear injection into Xenopus oocytes, and current recording from the oocytes under voltage clamp were described previously (Fischer et al., 1997; Kew et al., 1998) . Current responses were evoked once every 2.5 min by applying approximately half-maximal concentrations of the NMDA receptor coagonists L-glutamate (0.5-2.7 M) and glycine (0.07-0.4 M). After an initial series of control responses, Ro 63-1908 (0.01-10 M) was added to the basal saline and the agonist containing solutions superfusing the oocyte. At the lower concentrations the compound was applied up to 30 min for approaching equilibrium inhibition.
Measurements of intracellular free Na ϩ and Ca 2ϩ concentrations were performed using imaging methods as described by Fischer et al. (1997) . To calculate the mean values from these experiments, at least three independent experiments with triplicates were performed.
Cortical Neurons. Cells were used after 10 to 14 days in vitro (see Fischer et al., 1997) . Whole-cell voltage-clamp recordings were performed as described (Kew et al., 1996) . Briefly, cells were continuously superfused at room temperature with saline containing 149 mM NaCl, 3.25 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES, 11 mM D-glucose, pH 7.35, with an osmolarity of 350 mOsm adjusted with sucrose. Patch pipettes had a resistance of approximately 2 to 4 M⍀ when filled with a solution containing 120 mM CsF, 10 mM CsCl, 11 mM EGTA, 0.5 mM CaCl 2 , 10 mM HEPES, pH 7.25, with osmolarity adjusted to 330 mOsm with sucrose. Whole cell recordings were made at a holding potential of Ϫ60 mV using an Axopatch 200A amplifier (Axon Instruments, Foster City, CA). Pipette seal resistances were typically Ͼ10 gigaohms, and pipette capacitance transients were minimized both before and after membrane breakthrough. No series resistance compensation was applied. Drugs were diluted from concentrated stock into a modified version of the superfusion solution lacking MgCl 2 and including 30 M glycine. Drugs were applied to cells by fast superfusion from double-or triplebarreled capillary assemblies (internal capillary diameter 320 m). Currents were filtered (cut-off frequency 5 kHz), digitized using a Digidata 1200 digitizer (Axon Instruments), and captured on-line using pCLAMP6 software (Axon Instruments).
In Vitro Toxicity Experiments
Cortical neuronal cultures and subsequent toxicity experiments [glutamate, kainate, and oxygen-glucose deprivation (OGD)] were performed as described by Fischer et al. (1997) .
In Vivo Characterization
Pharmacokinetic Analysis of Ro 63-1908. Pharmacokinetic studies with Ro 63-1908 were performed in rats, dogs, mice, and cynomolgus monkeys following intravenous administration of bolus doses in the range of 2 to 10 mg/kg. Systemic clearance values were estimated under steady-state conditions, following continuous intravenous infusions in rats (7.5-15 mg/kg/h) and in cynomolgus monkeys (1.5-5 mg/kg/h). The plasma levels of Ro 63-1908 were measured using the high-performance liquid chromatography columnswitching method with fluorescence detection (Wyss et al., 2000) . Brain penetration of Ro 63-1908 was also examined, with cerebrospinal fluid and brain levels being analyzed using the same highperformance liquid chromatography method.
Audiogenic Seizures. Male DBA/2J mice (21 days old) were exposed to a 14-kHz sinusoidal tone at 110 dB for 60 s, which induced wild running progressing to tonic extensions of the limbs. Groups of eight mice were treated with either Ro 63-1908 (1.87, 3.75, 7.5, 15 , and 30 mg/kg i.p.) or MK-801 (0.03 to 1 mg/kg i.p.) 30 min before exposure to the sound. Animals not exhibiting a tonic seizure within the 60 s of sound exposure were considered protected.
Seizures Induced by NMDA. NMDA (0.15 g/2 l) was injected i.c.v. to MORO mice (18 -20 g), and the animals were observed for 5 min. With this treatment, mice exhibit wild running, clonic-tonic seizures (75% of the mice), and death (40% of the mice). Ro 63-1908 (0.3, 1, 3, 10 , and 30 mg/kg i.v.) or MK-801 (0.01-1 mg/kg,i.v.) were injected to groups of 8 mice 15 min before administration of NMDA. Animals not exhibiting clonic and tonic seizures were considered protected.
In all experiments the dose protecting 50% of the mice (ED 50 ) was calculated by probit analysis. These experiments were performed on a "blind" basis.
Motor Coordination. Mice (DBA/2J and MORO mice) were first trained to remain for 2 min on a revolving Rotarod apparatus (accelerating units increase from 3.5 to 35 rpm in 5 min). Ro 63-1908 and MK-801 were given i.v. or i.p. 15 or 30 min before the test. The latency time to fall off the Rotarod was determined (cut-off time used was 2 min). The same groups of mice were then used in the seizure tests. Results in the dose-response graph are given as the mean latency Ϯ S.E.M. in percentage of the control group. All experiments were done on a "blind" basis.
Locomotor Activity
The computerized Digiscan 16 Animal Activity Monitoring System (Omnitech, Columbus, OH) was used to quantify motor activity in male Sprague-Dawley rats. Immediately after the administration of Ro 63-1908 (1, 3, 10, and 30 mg/kg i.v.), rats were placed into the activity monitor for 4 h, and different parameters were measured, such as horizontal activity (total number of interruptions of the horizontal sensors during a given period). The mean from eight different animals was determined.
Middle Cerebral Artery Occlusion
Permanent focal cerebral ischemia was induced in adult (10 -11weeks) male Fischer 344/Ico old SPF rats (Iffa Credo, L'Arbresele, France), weighing between 220 and 230 g. The animals were fooddeprived for approximately 12 h before surgery. The left femoral artery and vein were cannulated to enable monitoring of blood pressure, blood gases, and continuous infusion of the compound. The left middle cerebral artery (MCA) was permanently occluded using bipolar coagulation in anesthetized (3% isoflurane in 70% air and 30% oxygen) animals as described by Shiraishi and Simon (1989) . Following surgery the animals were allowed to recover from the anesthesia and placed in a box with a swivel device to enable continuous infusion of the vehicle or test compound. Ro 63-1908 or vehicle was administered within 5 to 7 min after MCA occlusion as a bolus dose over 2 min, followed by an infusion over 5 h. A dose-response relationship for Ro 63-1908 was determined; bolus doses of 0.14, 0.7, 2.8, and 5.6 mg/kg followed by infusions of 0.28, 1.4, 5.6, and 11.2 mg/ kg/h for 5 h were administered as described above (n ϭ 9 -14 per group). The bolus ϩ infusion dosing regimen is akin to what may be used for neuroprotective agents in patients.
Measurement of Infarct Volume. The animals were deeply anesthetized with isoflurane 48 h after MCA occlusion and decapitated. Brains were immersion-fixed in 3.8% buffered formaldehyde for 5 days and automatically processed for embedding in paraffin (Bavimed 2050Z2; Haska AG, Bern, Switzerland) through a series of ethanol baths (70 -100%) into xylol and paraffin over 21 h. Serial coronal sections (10 m thick, three brains per block) were cut at 1-mm intervals through the forebrain and stained with toluidine blue. The boundaries of the infarcted cerebral cortex and neostriatum were marked by an unbiased observer and traced from a monitor (at 21ϫ magnification) onto a digitizing tablet interfaced to an image analysis system (DiaSys Datalab; H. Meyer, Thöringen, Switzerland). The infarct volumes were calculated by numeric integration of the infarct areas on sequential slices without correction for edema. Statistical significance was calculated with ANOVA (BMDP; Statistical Solutions, Cork, Ireland), followed by a Bonferroni correction.
Investigation of the Effect of Ro 63-1908 on Vacuole Formation
A study was performed to assess the effects of 
Results
Binding Studies. In adult rat brain membranes, Ro 63-1908 ( Fig. 1) inhibited 3 H-MK-801 binding in a markedly biphasic manner (Fig. 2) with IC 50 values for the high-and low-affinity components of 0.002 and 97 M, respectively. Using 3 H-Ro 25-6981 to label NR2B subunit-containing receptors selectively in the adult forebrain of rat, Ro 63-1908 inhibited with a single high-affinity component and with an IC 50 of 10 nM. Ro 63-1908 had only a weak affinity for ␣ 1 -adrenergic receptors (Table 1) . In an additional 38 radioligand binding assays, Ro 63-1908 was without activity (extrapolated IC 50 values Ͼ1 M) with the exception of affinities for dopamine receptors (K i of 0.2, 0.7, and 3.9 M for huD 3 , huD 4 , and huD 2 , respectively) and binding sites (about 80% block at 0.1 M). In a functional test of dopamine-stimulated guanosine 5Ј-O-(3-thio)triphosphate binding, Ro 63-1908 acted as a weak antagonist at huD 2 and huD 4 receptors with IC 50 values approximately 10 times lower than the K i values (data not shown).
Electrophysiological Characterization of Ro 63-1908.
In Xenopus oocytes expressing recombinant rat NMDA receptor subtypes (NR1C ϩ NR2B, NR1F ϩ NR2B, NR1C ϩ NR2A, or NR1C ϩ NR2D), Ro 63-1908 blocked only currents of NR2B-containing receptors with high affinity (Table 1) . The presence of the NR1-subunit N-terminal insert (exon 5, present in NR1F, but missing in NR1C) increased the IC 50 about 2-fold. A similar small influence of exon 5 has been seen previously with Ro 25-6981 and ifenprodil (Fischer et al., 1997) . Thus, Ro 63-1908 shows a high specificity for NR2B-containing NMDA receptor subtypes. In comparison, CP 101,606 was 10 times less potent at blocking NR2B-subunit receptors (NR1C ϩ NR2B) than Ro 63-1908 (IC 50 values of 30 and 3 nM, respectively).
The effects of Ro 63-1908 on neonatal rat cultured cortical neurons (10 -14 days in vitro) expressing NR2B as the predominant NR2 subunit were studied using whole-cell patch clamp. As with other subtype-selective NMDA antagonists, such as ifenprodil and Ro 25-6981, Ro 63-1908 exhibited a state-dependent antagonism of NR2B-containing NMDA receptors. In the presence of Ro 63-1908, small currents, elicited by very low glutamate site agonist concentrations, were potentiated, whereas larger currents elicited by higher agonist concentrations were inhibited (Fig. 3A) . Furthermore, with increasing levels of receptor activation, the rate and percentage of receptor blockade by Ro 63-1908 increased (Fig.  3B) . d Delayed outward current in cultured rat cortical neurons activated by voltage step from Ϫ80 mV to ϩ50 mV. e Cells were exposed to 100 M glutamate and 10 M glycine for 16 h and lactate dehydrogenase (LDH) was measured in the culture supernatant.
f Cells were exposed for 60 min to combined deprivation of oxygen and glucose, and LDH was measured after a recovery phase of 16 h in the culture supernatant.
g Cells were exposed to 500 M kainate for 16 h and LDH was measured in the culture supernatant. 
Downloaded from
The activity of Ro 63-1908 was also investigated at voltagegated Ca 2ϩ channels and delayed-rectifier K ϩ channels in cultured rat cortical neurons. Ro 63-1908 (10 M) blocked 10 Ϯ 1% of the Ba 2ϩ inward current through Ca 2ϩ channels (voltage steps from Ϫ80 mV to 10 mV) and 18 Ϯ 1% of the K ϩ outward current (steps from Ϫ80 to 40 mV). The effect on the fast voltage-activated Na ϩ current was studied in mouse neuroblastoma Neuro-2A cells because of better voltageclamp conditions. When the cells were clamped to a holding potential causing 50% inactivation of the Na ϩ channel under control conditions (Ϫ70 mV), Ro 63-1908 (10 M) decreased the peak Na ϩ current by 13 Ϯ 7% (voltage pulses to 0 mV). In conclusion, voltage-operated ion channels were only weakly inhibited at a high concentration of the compound.
Neuroprotection Studies of Ro 63-1908 in Vitro. Ro 63-1908 showed concentration-dependent protection against neurotoxicity induced by either exposure of cultured rat cortical neurons to glutamate (300 M, 16 h) or by combined deprivation of oxygen and glucose (OGD, 60 min; Fig. 4 Tables 2 and 3) .
The main pharmacokinetic parameters are shown in Table  4 . Ro 63-1908 demonstrated a high systemic clearance in rodents, dogs, and cynomolgus monkeys. In rodents and dogs the clearance exceeded liver blood flow and may involve extrahepatic metabolism (preliminary data showed a blood/ plasma partitioning of 1). Ro 63-1908 penetrated rapidly into the tissues and had a large volume of distribution in all species. In rodents Ro 63-1908 was rapidly eliminated after bolus dosing with a terminal half-life of 0.6 Ϯ 0.2 h, whereas in monkeys and dogs the terminal half-life was around 1.6 h.
Anticonvulsant Properties of Ro 63-1908. Ro 63-1908 was active against sound-induced seizures in DBA/2 mice with an ED 50 of 4.50 (2.86 -6.61) mg/kg i.p., when administered 30 min before the test. The dose required to produce a full anticonvulsant effect was not associated with a Rotarod deficit (Fig. 5A) . At 100 mg/kg i.p., only 10% motor deficit was obtained (data not shown). In MORO mice, Ro 63-1908 dose Locomotor Activity Profile of Ro 63-1908 in Rats. Ro 63-1908 produced an increase of horizontal activity, as shown in Fig. 5B , at doses of 1, 3, and 10 mg/kg i.v. This effect started immediately after the administration of the compound and lasted for 120 min. At 30 mg/kg, an initial decrease of the horizontal activity was observed, which was followed by an increase of the activity (Fig. 5B) . The rapid onset of these effects after i.v. injection is indicative of a fast penetration of Ro 63-1908 into brain. In contrast to results with nonselective NMDA receptor open-channel blockers, such as MK-801, rats administered Ro 63-1908 did not exhibit stereotypies such as head weaving and turning behavior.
Neuroprotective Effects in Vivo of Ro 63-1908. Ro 63-1908 administered after cerebral ischemia produced a dose-related decrease in the volume of cortical damage with maximum protection of 42% being seen after a dosing regimen of 5.6 mg/kg bolus followed by an infusion of 11 mg/kg/h. In a second experiment, a dosing regimen of 2.8 ϩ 5.6 mg/ kg/h gave similar protection of 39%, suggesting that the extent of protection achieved reached a plateau level (Fig.  6A) . There was no protection seen in the caudate nucleus because the lenticulostriate artery, which is a branch of the MCA serving the caudate nucleus, is permanently occluded in this model of focal ischemia.
The extent of protection seen with Ro 63-1908 is comparable with that seen with Ro 25-6981, as illustrated in the second experiment (Fig. 6B) . The optimum neuroprotective effect of 39% protection was seen at a mean plasma concentration ranging from 465 to 534 ng/ml (Ϸ1.5 M; see Table 5 ), with little variability between animals (coefficient of variation Ϸ 10%). A further doubling of the dose and hence the plasma concentration did not significantly increase the percentage of cortical protection seen with Ro 63-1908. The maximum neuroprotective concentrations are fully consistent with the inhibition of glutamate toxicity by Ro 63-1908 in cultured cortical neurons, where an IC 50 of 0.2 M was found and a full protection was seen at 2 M. These dosing regimens of Ro 63-1908 were without effect on the CNS or on cardiovascular parameters (mean arterial blood pressure and heart rate) in these animals when measured at 0.5, 2 and 5 h following the start of dosing (data not shown).
Effect of Ro 63-1908 on Vacuoles in the Cingulate Cortex. No vacuoles were seen in any of the sections of cingulate cortex from saline-treated animals, but vacuoles were found in cingulate cortex neurons in every MK-801-treated animal. Vacuoles were not found within cingulate cortex neurons of any animal treated with Ro 63-1908, even though plasma levels far in excess of maximum neuroprotective levels were reached, i.e., between 1650 and 1900 ng/ml.
Discussion
Ro 63-1908 is a high-affinity, subtype-selective NMDA receptor antagonist that only blocks NMDA receptors containing the NR2B subunit. The selectivity for NR2B versus NR2A subunits is Ͼ20,000-fold. Furthermore, Ro 63-1908 shows a high specificity for NMDA receptor subtypes over other types of receptors and ion channels apart from dopamine receptors and binding sites. The physiological significance of activities at dopamine receptors and binding sites is presently unclear but seems unlikely to represent serious concerns for side-effects. Ro 63-1908 was a potent neuroprotectant in excitotoxicity models in vitro that mimic pathophysiological conditions occurring in stroke and traumatic brain injury. Furthermore, Ro 63-1908 produced a dose-dependent neuroprotection of the ischemic infarct in an in vivo rat model of stroke, namely, permanent occlusion of the middle cerebral artery. Maximal protection was reached with plasma levels around 450 ng/ml, and the protection achieved was comparable with that reached with nonselective NMDA receptor The concentration-dependent protection by Ro 63-1908 against glutamate or OGD-induced toxicity is shown. After 12 days, in vitro cultured cortical neurons were exposed to glutamate (300 M) and glycine (1 M) or to OGD. Neuronal cell death was assessed qualitatively by phasecontrast microscopy and quantified by determination of lactate dehydrogenase activity in the cell culture supernatant. The difference between control cultures and glutamate-exposed cultures was taken as 100% lactate dehydrogenase release. At least three independent experiments were performed in quadruplicate. Arithmetic means of the quadruplicates are shown for each experiment. blockers such as MK-801 or 3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid (for review see Gill et al., 1999) . The activity-dependent mode of action of Ro 63-1908 favors the block of persistently activated NMDA receptors that occurs in ischemic brain areas following stroke and traumatic brain injury (Kew et al., 1996; Gill et al., 1999) . This activity dependence, together with subtype selectivity, results in an improved safety profile of Ro 63-1908 compared with nonselective NMDA antagonists such as MK-801 and aptiganel (for reviews see Kemp and Kew, 1999; McBurney, 1997) . Thus, there were no significant effects on blood pressure or heart rate in conscious animals and no stereotypic behaviors or -1908 (1-30 mg/kg) was administered i.p., and 25 min after dosing, the animals were tested on the Rotarod, the latency to fall off the Rotarod was measured, and the mice were then exposed to sound. The results are given as the mean latency (percentage of the control group) to fall off the Rotarod and as the percentage of animals demonstrating anticonvulsant activity. Groups of eight mice were used. B, effects of Ro 63-1908 on locomotor activity following acute i.v. administration were measured. Each point represents the mean horizontal activity measured for n ϭ 8 rats.
Fig. 6.
Neuroprotective effects of Ro 63-1908 in a rat model of focal ischemia. The left MCA was permanently occluded using bipolar coagulation, and Ro 63-1908 was administered 5 min after the occlusion using various dosing regimens. Ro 63-1908 was administered as an i.v. bolus over 2 min followed by an infusion over 5 h. A, there was a dose-related significant neuroprotective effect of Ro 63-1908 against cortical damage (ANOVA, F ϭ 24.46; p ϭ 0.0001) but not against caudate damage (ANOVA, F ϭ 1.22; P Ͼ 0.3). The doses of 0.7 mg/kg ϩ 1.4 mg/kg/h and 5.6 mg/kg ϩ 11.2 mg/kg/h gave a significant neuroprotective effect ‫,ء(‬ P Ͻ 0.01, Bonferroni correction). B, there was a significant neuroprotective effect of Ro 63-1908 against cortical damage at both doses tested (ANOVA, F ϭ 37.23; p ϭ 0.0001); once again, no significant protection was seen against caudate damage. Ro 25-6981 at a dose of 1.25 mg/kg ϩ 2.92 mg/kg/h for 5 h also gave a significant neuroprotective effect. Each bar represents the mean Ϯ S.E.M. for 9 -14 animals per group; ‫,ء‬ P Ͻ 0.01, Bonferroni correction. circling were seen. In separate behavioral studies in rats, the only observable behavior was increased locomotor activity after acute i.v. bolus injection of Ro 63-1908. An increase in locomotor activity occurred at doses of 1 and 3 mg/kg, whereas an initial decrease was followed by an increase at higher doses (10 and 30 mg/kg). The significance of the locomotor stimulant effect for human behavior is unclear, but the lack of stereotyped behaviors suggests that, like ifenprodil and CP 101,606, this compound may have a reduced psychotomimetic potential compared with nonselective antagonists. Ro 63-1908 prevented sound-induced seizures at doses that did not effect motor coordination as measured on the Rotarod. This is in contrast to the nonselective NMDA receptor antagonists such as MK-801 in which there is no separation between anticonvulsant effects and motor incoordination (Tricklebank et al., 1989) . No proconvulsant activity was found with Ro 63-1908. Ro 63-1908 did not induce morphological changes (vacuoles) in the retrosplenial and cingulate cortical neurons following infusion of 30 mg/kg/h of Ro 63-1908 for 5 h. This resulted in plasma concentrations 3-fold higher than the therapeutic level in the stroke model. All MK-801-treated animals, which served as a positive control, had vacuoles in the retrosplenial and cingulate cortex, as shown previously (Olney et al., 1989; Hargreaves et al., 1993) . The neuroprotective doses of MK-801 are close to those producing vacuoles in the cingulate cortex (Gill et al., 1991; Hargreaves et al., 1993) . Eliprodil, which is also an NR2B subtype-selective NMDA antagonist, did not produce vacuoles in the retrosplenial or cingulate cortex (Carter et al., 1997) . Thus, it appears that, unlike nonselective NMDA antagonists, NR2B subtypeselective NMDA antagonists do not induce neuronal vacuolization in cortical neurons.
The nonselective NMDA antagonists show adverse CNS and cardiovascular side effects at maximum protective levels in this model of focal ischemia, and these effects have proven to be dose-limiting in the clinic (McBurney, 1997; Albers et al., 2001) . In humans the dose-limiting side effects seen with the nonselective NMDA antagonists were hypertension, agitation, ataxia, sedation, psychosis, and hallucinations (for review see Muir and Lees, 1995; Lees, 1997) .
The atypical NMDA antagonist ifenprodil was demonstrated to be neuroprotective in animal models without the adverse side effects of compounds like MK-801, aptiganel, and selfotel (Gotti et al., 1988) . Ifenprodil was the first in this class of NMDA antagonists selective for the NR2B subunit of the NMDA receptor (Gotti et al., 1988; Williams, 1993) and was shown to have a novel activity-dependent mechanism of action (Kew et al., 1996 . CP 101,606 is a structural analog of ifenprodil that is also a selective antagonist of NMDA NR2B subunits but, unlike ifenprodil, lacks ␣ 1 -adrenoceptor activity (Chenard et al., 1995; Menniti et al., 1997) . CP 101,606 was demonstrated to protect against glutamateinduced toxicity in neuronal cultures with a potency similar to that of MK-801 (Menniti et al., 1997) . It was also found to be neuroprotective in an acute model of focal ischemia in the cat . In Phase I trials in patients, it did not show any of the cardiovascular or CNS side effects seen with the nonselective NMDA antagonists Merchant et al., 1999) . This compound has been in Phase II clinical trials for brain trauma, although recent press reports indicate that clinical studies have now been discontinued due to lack of efficacy.
In conclusion, it appears that activity-dependent NR2B subtype-selective NMDA antagonists, such as Ro 63-1908, show potential for the treatment of stroke and brain trauma. They have advantages over nonselective competitive and ion channel-blocking NMDA antagonists in that they have a much improved tolerability in animals and also, based on initial reports, in humans Bullock et al., 1999) . Therefore, it is conceivable that maximally neuroprotective doses of these compounds could be achieved in humans without cardiovascular or CNS side effects. 0.14 ϩ 0.28 8.6 Ϯ 4 Ͻ50 Ͻ50 (n ϭ 11) 0.7 ϩ 1.4 25.4 Ϯ 5 103 Ϯ 14 128 Ϯ 22 (n ϭ 12) (n ϭ 5) (n ϭ 3) 0.7 ϩ 1.4 29.2 Ϯ 4 105 Ϯ 13 130 Ϯ 12 (n ϭ 9) (n ϭ 4) (n ϭ 4) 2.8 ϩ 5.6 38.6 Ϯ 3 465 Ϯ 29 534 Ϯ 40 (n ϭ 10) (n ϭ 5) (n ϭ 3) 5.6 ϩ 11.2 42.5 Ϯ 3 1078 Ϯ 82 1180 Ϯ 196 (n ϭ 10) (n ϭ 5) (n ϭ 5)
a Ro 63-1908 was administered as a bolus dose over 2 min followed by an infusion over 5 h.
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